PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportscarcinoma
MeSH D002277 - carcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D009375:Glandular and epithelial neoplasms
0 Companies
0 Drugs
Success rate
D002277: 
Carcinoma
18 Companies
3 Drugs
$
Success rate
D000069295:Mammary analogue secretory carcinoma
0 Companies
0 Drugs
Success rate
D000077216:Ovarian epithelial carcinoma
1 Company
1 Drug
$
Success rate
D000077274:Nasopharyngeal carcinoma
1 Company
1 Drug
$
Success rate
D000230:Adenocarcinoma
24 Companies
3 Drugs
$
Success rate
D002278:Carcinoma in situ
0 Companies
0 Drugs
Success rate
D002280:Basal cell carcinoma
29 Companies
2 Drugs
$
Success rate
D002281:Basosquamous carcinoma
0 Companies
0 Drugs
Success rate
D002286:Ehrlich tumor carcinoma
0 Companies
0 Drugs
Success rate
D002287:Krebs 2 carcinoma
0 Companies
0 Drugs
Success rate
D002291:Papillary carcinoma
0 Companies
0 Drugs
Success rate
D002294:Squamous cell carcinoma
21 Companies
11 Drugs
$
Success rate
D002295:Transitional cell carcinoma
8 Companies
9 Drugs
$
Success rate
D018196:Adenosquamous carcinoma
0 Companies
0 Drugs
Success rate
D018286:Giant cell carcinoma
0 Companies
0 Drugs
Success rate
D018287:Large cell carcinoma
0 Companies
0 Drugs
Success rate
D018288:Small cell carcinoma
20 Companies
3 Drugs
$
Success rate
D018289:Verrucous carcinoma
0 Companies
0 Drugs
Success rate
D018827:Lewis lung carcinoma
0 Companies
0 Drugs
Success rate
D065646:Anaplastic thyroid carcinoma
0 Companies
0 Drugs
Success rate
D000093284:Non-muscle invasive bladder neoplasms
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Accord HealthcareCarmustine Carmustine  2022-12-27   
Alembic PharmaceuticalsCarmustine Carmustine  2023-10-20   
Amneal PharmaceuticalsCarmustine Carmustine  2018-10-16   
Avet LifesciencesCarmustine Bicnu  1982-01-01   
AzurityCarmustine Gliadel  1996-09-23   
Dr Reddys LaboratoriesCarmustine Carmustine  2020-10-22   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
63%
15/24
Phase 2
22%
8/37
Phase 3
21%
3/14
Approved: 3Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Bayer
ORTATAXEL,
REFAMETINIB,
Rogaratinib,
Bay1163877,
Taxane
Bristol Myers Squibb
Lucitanib
Eli Lilly
Lucitanib,
Galunisertib,
Enzastaurin,
CIXUTUMUMAB,
ICRUCUMAB,
PREXASERTIB,
Ly3435151,
LY-2584702,
LY2510924
Jiangsu Hengrui Medicine
Camrelizumab,
Famitinib,
Nimotuzumab,
Rivoceranib,
Nedaplatin,
Shr1210
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use